{"id":"jmt103","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"2-5%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, JMT103 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.","oneSentence":"JMT103 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:36.501Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06314698","phase":"PHASE3","title":"Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-04-01","conditions":"Multiple Myeloma, Bone Diseases","enrollment":478},{"nctId":"NCT06221072","phase":"PHASE3","title":"A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-04-05","conditions":"Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors","enrollment":1360},{"nctId":"NCT04630522","phase":"PHASE1","title":"Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors","status":"COMPLETED","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2020-10-31","conditions":"Bone Metastases From Solid Tumors","enrollment":295},{"nctId":"NCT05813665","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2023-04","conditions":"Giant Cell Tumor of Bone","enrollment":146},{"nctId":"NCT04255576","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2019-10-10","conditions":"Giant Cell Tumor of Bone","enrollment":139},{"nctId":"NCT05278338","phase":"PHASE2","title":"Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-04-21","conditions":"Postmenopausal Osteoporosis","enrollment":200},{"nctId":"NCT05397938","phase":"PHASE2","title":"Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-06-15","conditions":"Glucocorticoid Induced Osteoporosis","enrollment":231},{"nctId":"NCT04198480","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2020-01-24","conditions":"Hypercalcemia of Malignancy","enrollment":17},{"nctId":"NCT03550508","phase":"PHASE1","title":"Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2018-05-21","conditions":"Bone Metastases","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JMT103","genericName":"JMT103","companyName":"Shanghai JMT-Bio Inc.","companyId":"shanghai-jmt-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JMT103 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}